Does the media refer more to BEAM or PRME?

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.23 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRME or CRSP?

In the previous week, CRISPR Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 6 mentions for Prime Medicine. CRISPR Therapeutics' average media sentiment score of 0.75 beat Prime Medicine's score of 0.44 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or VRDN?

In the previous week, Prime Medicine had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Prime Medicine and 5 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.64 beat Prime Medicine's score of 0.44 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLS or PRME?

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 6 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat SELLAS Life Sciences Group's score of 0.21 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRME or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Pharvaris' return on equity of -61.40% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Prime Medicine -4,613.11% -188.27% -59.11% Pharvaris N/A -61.40% -56.00%

Does the media prefer PRME or PHVS?

In the previous week, Pharvaris had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Pharvaris and 6 mentions for Prime Medicine. Pharvaris' average media sentiment score of 0.63 beat Prime Medicine's score of 0.44 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prime Medicine (PRME) Competitors

$2.98 -0.01 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.00 +0.02 (+0.67%)

As of 04:43 PM Eastern

Compare

PRME vs. BEAM, CRSP, VRDN, SLS, and PHVS

Should you buy Prime Medicine stock or one of its competitors? Prime Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Viridian Therapeutics (VRDN), SELLAS Life Sciences Group (SLS), and Pharvaris (PHVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prime Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Beam Therapeutics has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to Prime Medicine's net margin of -4,613.11%. Beam Therapeutics' return on equity of -30.71% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	17.99	-$79.99M	-$0.86	N/A
Prime Medicine	$4.63M	115.37	-$201.14M	-$1.06	N/A

Beam Therapeutics currently has a consensus price target of $49.00, suggesting a potential upside of 101.36%. Prime Medicine has a consensus price target of $7.47, suggesting a potential upside of 153.73%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.23 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to CRISPR Therapeutics?

Prime Medicine (NASDAQ:PRME) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Prime Medicine has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

CRISPR Therapeutics has a net margin of -3,368.72% compared to Prime Medicine's net margin of -4,613.11%. CRISPR Therapeutics' return on equity of -24.39% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Prime Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	115.37	-$201.14M	-$1.06	N/A
CRISPR Therapeutics	$3.51M	1,493.49	-$581.60M	-$4.76	N/A

In the previous week, CRISPR Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 6 mentions for Prime Medicine. CRISPR Therapeutics' average media sentiment score of 0.75 beat Prime Medicine's score of 0.44 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine currently has a consensus price target of $7.47, suggesting a potential upside of 153.73%. CRISPR Therapeutics has a consensus price target of $67.94, suggesting a potential upside of 25.32%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts clearly believe Prime Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Prime Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Viridian Therapeutics?

Prime Medicine (NASDAQ:PRME) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

In the previous week, Prime Medicine had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Prime Medicine and 5 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.64 beat Prime Medicine's score of 0.44 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Prime Medicine shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Prime Medicine has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Viridian Therapeutics has a net margin of -505.86% compared to Prime Medicine's net margin of -4,613.11%. Viridian Therapeutics' return on equity of -72.97% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Prime Medicine has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	115.37	-$201.14M	-$1.06	N/A
Viridian Therapeutics	$70.85M	30.82	-$342.60M	-$3.37	N/A

Prime Medicine currently has a consensus target price of $7.47, indicating a potential upside of 153.73%. Viridian Therapeutics has a consensus target price of $38.69, indicating a potential upside of 100.77%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts plainly believe Prime Medicine is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Prime Medicine beats Viridian Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

SELLAS Life Sciences Group currently has a consensus price target of $10.00, suggesting a potential downside of 15.65%. Prime Medicine has a consensus price target of $7.47, suggesting a potential upside of 153.73%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

SELLAS Life Sciences Group has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. SELLAS Life Sciences Group's return on equity of -35.91% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 6 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat SELLAS Life Sciences Group's score of 0.21 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group has a beta of 2.56, suggesting that its stock price is 156% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Prime Medicine. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Prime Medicine	$4.63M	115.37	-$201.14M	-$1.06	N/A

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Prime Medicine beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Pharvaris?

Prime Medicine (NASDAQ:PRME) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Pharvaris' return on equity of -61.40% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Pharvaris	N/A	-61.40%	-56.00%

In the previous week, Pharvaris had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Pharvaris and 6 mentions for Prime Medicine. Pharvaris' average media sentiment score of 0.63 beat Prime Medicine's score of 0.44 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Prime Medicine shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 11.8% of Pharvaris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pharvaris has lower revenue, but higher earnings than Prime Medicine. Pharvaris is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	115.37	-$201.14M	-$1.06	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Prime Medicine currently has a consensus price target of $7.47, indicating a potential upside of 153.73%. Pharvaris has a consensus price target of $59.87, indicating a potential upside of 91.94%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Prime Medicine has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, meaning that its share price is 346% less volatile than the broader market.

Summary

Prime Medicine beats Pharvaris on 9 of the 16 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$539.61M	$3.84B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-2.81	13.44	274.42	26.03
Price / Sales	116.55	1,285.38	600.72	89.51
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	4.44	16.64	10.92	6.32
Net Income	-$201.14M	-$22.67M	$3.50B	$361.43M
7 Day Performance	2.59%	-2.99%	-2.07%	-1.66%
1 Month Performance	-18.94%	-10.68%	-6.32%	-3.93%
1 Year Performance	-55.40%	21.44%	8.92%	2.82%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	3.5888 of 5 stars	$2.98 -0.3%	$7.47 +150.7%	-46.5%	$540.51M	$4.63M	N/A	146	Gap Up
BEAM Beam Therapeutics	2.5915 of 5 stars	$25.94 +0.0%	$49.00 +88.9%	+1.1%	$2.70B	$139.74M	N/A	540	Gap Up
CRSP CRISPR Therapeutics	2.8097 of 5 stars	$58.94 -0.2%	$67.94 +15.3%	-16.2%	$5.71B	$3.51M	N/A	393
VRDN Viridian Therapeutics	2.7794 of 5 stars	$22.05 -0.3%	$38.69 +75.5%	-10.7%	$2.49B	$70.85M	N/A	252
SLS SELLAS Life Sciences Group	0.4068 of 5 stars	$11.98 -0.4%	$10.00 -16.5%	+570.4%	$2.42B	N/A	N/A	13

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, CRSP, VRDN, SLS, and PHVS

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to CRISPR Therapeutics?

Summary

How does Prime Medicine compare to Viridian Therapeutics?

Summary

How does Prime Medicine compare to SELLAS Life Sciences Group?

Summary

How does Prime Medicine compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, CRSP, VRDN, SLS, and PHVS

How does Prime Medicine compare to Beam Therapeutics?

Which has more risk and volatility, BEAM or PRME?

Is BEAM or PRME more profitable?

Which has higher earnings & valuation, BEAM or PRME?

Do analysts prefer BEAM or PRME?

Do institutionals & insiders have more ownership in BEAM or PRME?

Does the media refer more to BEAM or PRME?

Summary

How does Prime Medicine compare to CRISPR Therapeutics?

Which has more risk and volatility, PRME or CRSP?

Is PRME or CRSP more profitable?

Which has preferable valuation and earnings, PRME or CRSP?

Does the media prefer PRME or CRSP?

Do analysts rate PRME or CRSP?

Do institutionals and insiders have more ownership in PRME or CRSP?

Summary

How does Prime Medicine compare to Viridian Therapeutics?

Does the media refer more to PRME or VRDN?

Do insiders and institutionals hold more shares of PRME or VRDN?

Which has more risk & volatility, PRME or VRDN?

Is PRME or VRDN more profitable?

Which has higher valuation and earnings, PRME or VRDN?

Do analysts prefer PRME or VRDN?

Summary

How does Prime Medicine compare to SELLAS Life Sciences Group?

Do analysts recommend SLS or PRME?

Is SLS or PRME more profitable?

Does the media favor SLS or PRME?

Which has more volatility & risk, SLS or PRME?

Which has preferable earnings and valuation, SLS or PRME?

Do institutionals & insiders have more ownership in SLS or PRME?

Summary

How does Prime Medicine compare to Pharvaris?

Is PRME or PHVS more profitable?

Does the media prefer PRME or PHVS?

Do insiders & institutionals have more ownership in PRME or PHVS?

Which has stronger earnings & valuation, PRME or PHVS?

Do analysts prefer PRME or PHVS?

Which has more risk and volatility, PRME or PHVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools